Skip to main content
Figure 4 | Diabetology & Metabolic Syndrome

Figure 4

From: Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties

Figure 4

Effects of sitagliptin treatment on pancreatic mRNA expression of mediators of inflammation, angiogenesis and proliferation: IL-1β, VEGF and PCNA. (A) mRNA expression of pancreatic IL-1β in untreated diabetic ZDF rats was significantly increased (p < 0.01) in contrast to lean control rats; in the sitagliptin-treated diabetic group, overexpression of IL-1β was significantly prevented (p < 0.001). Overexpression (p < 0.001) of VEGF (B) and PCNA (C) mRNA in ZDF diabetic rats treated with sitagliptin for 6 weeks when compared with untreated diabetic rats. Statistical comparisons between groups were performed using one-way ANOVA and the post-hoc Bonferroni test (p < 0.05, p < 0.01 and p < 0.001 for one, two or three symbols, respectively; n = 5 per group).

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us